Medical devices, healthcare technology and the business of care
PMA approval · P250036

PGDx elio tissue complete CDx

Personal Genome Diagnostics, Inc. · Decision date Jul 30, 2026

FDA DECISIONP250036

What did the FDA approve?

FDA records P250036 as an original PMA application. The recorded decision is approval, dated Jul 30, 2026.

FDA approval order statement

PGDx elio tissue complete CDx is a qualitative next-generation sequencing-based in vitro diagnostic device that uses a high-throughput hybridization-based capture technology utilizing DNA isolated from formalin-fixed paraffin embedded tumor tissue. The PGDx elio tissue complete CDx targeted panel can detect single nucleotide variants, small insertions and deletions, copy number amplifications, and translocations. It is intended to be used as a companion diagnostic to identify melanoma patients who may benefit from treatment with the targeted therapies listed in Table 1.1 below in accordance with the approved therapeutic product labeling.
Regulatory pathway
Original PMA
Clinical specialty
Medical Genetics
Decision date
Jul 30, 2026

FDA source record

Regulatory record facts

Identifier
P250036
Regulatory pathway
Premarket approval application
Product code
PQP
Decision code
APPR
Decision date
Jul 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250036 received

    Application receipt date recorded by FDA.

  2. P250036 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250036. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Personal Genome Diagnostics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3600 Boston St., Suite 10, Blatimore, MD, 21224

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records